INmune Bio and Quantum Computing Inc. Collaborate to Advance Alzheimer's Research

INmune Bio Inc. and Quantum Computing Inc. have announced a partnership aimed at enhancing Alzheimer's drug research by applying quantum computing and AI. This collaboration seeks to identify new potential applications for XPro, an investigational treatment for Alzheimer's disease, leveraging INmune Bio's clinical research data and QCi's Dirac-3S quantum optimization technology.

This initiative marks Quantum Computing Inc.'s initial foray into the pharmaceutical market, showcasing the potential of quantum computing in drug development. The partnership aims to discover diseases influenced by the same biological mechanisms targeted by XPro and prioritize indications with high success potential.

In addition to advancing drug research, the collaboration will serve as a case study for quantum computing applications, with INmune Bio evaluating broader potential applications for XPro. The integration of quantum computing seeks to uncover insights and create a replicable process for future research.